Search for: [Abstract = "including occludin and claudin. Research is needed to investigate how the SCFA profile is linked to intestinal barrier integrity and severity of intestinal mucosal inflammation as well as severity of clinical symptoms in patients with IBD. Such data would facilitate developments in SCFA supplementation as an adjunctive treatment for patients with IBD aimed at relieving symptoms and intestinal mucosal healing. Objectives The aim of the study was to assess the qualitative and quantitative changes in fecal SCFA levels in patients with IBD during remission and active disease, as compared with controls, using capillary electrophoresis with spectrophotometric detection \(CE\-UV\). Another objective was to determine an association between the fecal SCFA profile and selected inflammatory markers \(C\-reactive protein \[CRP\], calprotectin\) as well as serum proinflammatory and anti\-inflammatory markers \(TNF\-α, IL\-6, IL\-10, IL\-17, and IL\-22\) in patients with inactive and active IBD as well as controls. Finally, the aim of the study was to assess mucosal mRNA expression in large intestinal mucosa for selected inflammatory markers \(IL\-6\), enzymes \(peroxisome proliferator\-activated receptor gamma \[PPAR\-γ\], inducible nitric oxide synthase \[iNOS\]\), and tight junction proteins \(zonula occludens\-1 \[ZO\-1\], claudin\-2, occludin\) in patients with inactive and active IBD as well as controls, using real"]

Number of results: 1